$JUNS +57% Premarket 🚀 🔹 Jupiter Neurosciences ripping after securing a $100M term sheet for exclusive U.S. rights to ALA-002 📈 🔹 ALA-002 is a next-gen MDMA

$JUNS +57% Premarket 🚀 🔹 Jupiter Neurosciences ripping after securing a $100M term sheet for exclusive U.S. rights to ALA-002 📈 🔹 ALA-002 is a next-gen MDMA therapeutic designed for improved cardiovascular safety + reduced abuse liability 🧠 🔹 Deal adds a major new CNS asset alongside Jupiter’s…